Bouda Christopher sold $1.8M of DHR

Bouda Christopher (VP, Chief Accounting Officer) sold 7,598 shares of DANAHER CORP /DE/ (DHR) at an average of $234.56 ($234.54–$234.58, $1.78M total) across 2 trades on 2026-10-28.

Original reporting
SEC EDGAR · Bouda Christopher
Published Oct 29, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 9:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DHR
Neutral
high confidence
Mentioned
$DHR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DHRNeutralLow
01

Why it matters

The disclosure updates Danaher’s insider trading record, but it does not include any new guidance, earnings, deal, or regulatory action that would directly change valuation assumptions.

02

Market read

Traders may note insider selling, but the event is generally low signal for fundamentals absent accompanying corporate news.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; the filing does not provide intent or linkage to company outlook.

Relevance 6/10Novelty 3/10Timing: SEC Form 4 filed 2026-10-29, covering sales dated 2026-10-28.

Background

The article is an SEC Form 4 insider transaction report for Danaher Corp, filed by VP and Chief Accounting Officer Bouda Christopher.

Company-level read

Ticker impact

$DHRNeutralHigh confidence
Context

Danaher insider Bouda Christopher sold 7,598 shares in open-market transactions on 2026-10-28, totaling about $1.78M, per Form 4.

Expected impact

Likely limited near-term impact; traders may view it as modest supply/insider selling noise rather than a signal.

Evidence & confidence

The filing is an SEC Form 4 insider transaction. It provides transaction size and timing but no new operational, guidance, or regulatory information that would reprice Danaher’s fundamentals.

Market effects

No clear sector read-through; this is company-specific insider activity without new business developments.

None.

None.

Counterpoint

Absence of a 10b5-1 plan could prompt some traders to treat the sale as more meaningful than typical scheduled selling, potentially adding short-term caution.

Key entities

  • DANAHER CORP /DE/

    Danaher Corp, the company whose insider transaction is reported.

  • Bouda Christopher

    VP, Chief Accounting Officer who sold shares via open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DHRMed

Beckman Coulter receives FDA clearance for bacterial infection test

Beckman Coulter Diagnostics, part of Danaher Corporation, received FDA clearance for the Access MeMed BV assay, a blood test distinguishing bacterial from viral infections in patients aged 90 days and older. The test runs on the company's DxI 9000 and Access 2 immunoassay analyzers, providing results in 15 minutes. Developed with MeMed, the test measures immune-response proteins to generate a bacterial infection likelihood score.

$DHRMed

UBS reiterates Danaher stock Buy rating on Q3 results and outlook

UBS reiterated a Buy rating on Danaher (DHR) with a $260 price target, citing Q3 results and outlook. The stock, near its 52-week high, has risen 27.6% in six months. Danaher reported Q3 core revenue growth of 2.5% to 3.0% and adjusted earnings of $2.11 per share, exceeding expectations. Stifel also raised its price target to $260, noting strong nonrespiratory growth.